Cases
Lannett Company, Inc. (NYSE: LCI)
Securities Class Action
Overview
Overview
- Date:
- 12/1/2016
- Company Name:
- Lannett Company, Inc.
- Stock Symbol:
- LCI
- Class Period:
- FROM 9/12/2013 TO 11/3/2016
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Eastern District of Pennsylvania
NEW YORK, December 1, 2016 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Pennsylvania Eastern District Court on behalf of all persons or entities who acquired the Lannett Company, Inc. (NYSE: LCI) securities between September 12, 2013 to November 3, 2016 (the “Class Period”).
The complaint alleges that Lannett made false and/or misleading statements and/or failed to disclose: (1) that the Company's drug pricing relied on unsustainable pricing methodologies; (2) that Lannett lacked effective internal controls concerning its drug pricing methodologies; and (3) that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Lannett, to determine whether they unlawfully colluded with each other to fix generic drug prices. When this information was disclosed, shares of Lannett declined $6.25 per share.
If you acquired Lannett securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The complaint alleges that Lannett made false and/or misleading statements and/or failed to disclose: (1) that the Company's drug pricing relied on unsustainable pricing methodologies; (2) that Lannett lacked effective internal controls concerning its drug pricing methodologies; and (3) that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Lannett, to determine whether they unlawfully colluded with each other to fix generic drug prices. When this information was disclosed, shares of Lannett declined $6.25 per share.
If you acquired Lannett securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.